Literature DB >> 6938045

VACURG studies of conservative treatment.

D P Byar.   

Abstract

The results of these three studies clearly indicate that prostatic cancer is hormonally responsive, and many patients have experienced distinct benefit from estrogens or orchiectomy, especially with regard to relief of symptoms. The complexity of some of the reports of VACURG studies has led some to believe that this group was opposed to estrogens, but that is not true. However, the VACURG has shown that if estrogens are used in too high a dose and for the wrong patients, it is likely that an unnecessary number of cardiovascular deaths will result. The risk factors we have identified for estrogen induced cardiovascular complications may provide some guidance in deciding which patients to treat and may be helpful in sharpening questions to be asked in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6938045

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  2 in total

1.  Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.

Authors:  P Henriksson
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

2.  Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.

Authors:  Frank Kunath; Katrin Jensen; Mariona Pinart; Andreas Kahlmeyer; Stefanie Schmidt; Carrie L Price; Verena Lieb; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.